Quick Answer
Amylyx Pharmaceuticals, Inc. reported Net Income Loss of -$144.74 million for the year ending 2025.
- Amylyx Pharmaceuticals, Inc. showed an increase of +52.0% in Net Income Loss from 2024 to 2025.
- This data is from Amylyx Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: -$14.52 million | Q2 2021: -$21.92 million | Q3 2021: -$23.14 million | Q1 2022: -$47.85 million | Q2 2022: -$54.07 million | Q3 2022: -$53.76 million | Q1 2023: $1.57 million | Q2 2023: $22.07 million | Q3 2023: $20.89 million | Q1 2024: -$118.79 million | Q2 2024: -$72.70 million | Q3 2024: -$72.70 million | Q1 2025: -$35.91 million | Q2 2025: -$41.44 million | Q3 2025: -$34.39 million.
- Over the full 5 years of available data (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s Net Income Loss has declined by 64.6%.
- Historical annual values: Fiscal year 2025: -$144.74 million | Fiscal year 2024: -$301.74 million | Fiscal year 2023: $49.27 million | Fiscal year 2022: -$198.38 million | Fiscal year 2021: -$87.93 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: